TrialThe Journal of infectious diseases2024

Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial.

Carlos Fierro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.